PGS Preimplantation Diagnosis allows to eliminate the risk of genetic defects in a child even before a woman gets pregnant. By examining the embryo’s cells, the physicians are able to determine whether there are abnormalities in its DNA. The diagnosis is carried out as part of in vitro fertilization treatment program.
Risk of genetic defect increases with mother’s age. In case of women aged 35-40, 44.9% (statistics www.sart.org) of embryos have abnormal number of chromosomes (so called chromosomal aneuploidies) – regardless of the method of fertilization. This results in serious fetal genetic defects, including Down syndrome, Klineferter syndrome, Turner syndrome, Patau syndrome etc. Genetic abnormalities can lead to implantation failure and miscarriage, significantly decreasing treatment efficacy.
The chart below presents the probability of a genetic defect in a child depending on the mother’s age. It increases significantly in women above 35 years of age.
Therefore, PGS preimplantation diagnosis is recommended for patients older than 35.
Clinical studies carried out at the INVICTA Clinic in the group of over 200 couples with indications to PGS preimplantation diagnosis have demonstrated that embryo genetic testing doubles the chances for pregnancy in comparison with in vitro programs without PGS-NGS diagnosis.
Moreover, in vitro fertilization programs with PGS show higher embryo implantation rate, lower miscarriage rate and – what’s the most important from the patient’s perspective – over 100% higher efficacy of treatment.